Rabies immunoglobulin market is anticipated to grow at a significant CAGR of 6.1 % during the forecast period. Rabies is a fatal disease although preventable viral disease. It can spread to people and pets if they are bitten or scratched by a rabid animal. In the US, rabies is mostly found in wild animals such as bats, raccoons, skunks, and foxes. However, in many other countries dogs still carry rabies, and most rabies deaths in people across the globe are caused by dog bites. The increasing prevalence of rabies is expected to drive the rabies immunoglobulin market during the forecast period. According to the data published by Express Network Pvt. Ltd., An increasing number of people have been reporting about getting attacked/ bitten by dogs/monkeys, ever since the lockdown began. These bites can lead to rabies, a disease caused by a virus transmitted to the human body through the infected saliva of a dog, monkey, cat, or cattle if bitten by the said animal. Moreover, as per a 2017 study, Rabies causes over 20,000 deaths in India annually. Moreover, according to WHO, vaccination of at least 70% of dogs in areas at risk is now accepted as the most effective way of preventing human rabies deaths.

Segmental Outlook 

The global rabies immunoglobulin market is segmented based on type. Based on the type, the market is segmented into HRIG and ERIG. The HRIG segment is expected to hold a considerable share in the market during the forecast period. The vaccine provides immediate antibodies until the body can respond to the vaccine by actively producing antibodies of its own. The full dose of HRIG should be thoroughly infiltrated in the area around and into the wounds. The recommended dose of HRIG is 20 IU/kg body weight. This formula applies to all age groups, including children. For instance, in August 2019, the new KEDRAB Dose Calculator was launched, at the height of the US rabies season. The KEDRAB Dose Calculator helps healthcare providers quickly and accurately determine the correct volume of KEDRAB to administer to patients who have been exposed to rabies. KEDRAB is the only HRIG that may be stored at room temperature not exceeding 25°C (77°F) for up to one month. It should be used within one month; do not return to refrigeration.

Regional Outlooks

The global rabies immunoglobulin market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa, and Latin America).  The market can be analyzed for a particular region or country level as per the requirement.

Global Rabies Immunoglobulin Market Growth, by Region 2022-2028

The Asia-Pacific Region is Expected to Hold a Significant Share in the Global Rabies Immunoglobulin Marke 

Among all regions, the Asia-Pacific region is expected to hold a significant market share during the forecast period. The growing number of deaths due to rabies is creating demand for the rabies immunoglobulin market during the forecast period. For instance, according to the WHO, India is endemic to rabies accounting for 36% of the global deaths. The lack of awareness regarding rabies in India is not fully known and it causes 18,000-20,000 deaths every year. Further, about 30-60% of reported rabies cases and deaths in India occur in children under the age of 15 years as bites that occur in children are either unrecognized or unreported. 

Market Players Outlook

The major companies serving the global rabies immunoglobulin market include Bharat Serums and Vaccines Ltd. (BSV), CSL Behring, Grifols SA, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in April 2020, Grifols, a global producer of plasma-derived medicines launched a new 3-mL (900-IU) vial for HyperRAB used for treating rabies postexposure prophylaxis. The addition of a 3-mL (900-IU) option offers healthcare providers better convenience by potentially reducing the number of vials used during administration while cutting down on product and packaging waste in the process. The new vial size will also provide storage efficiencies for hospital pharmacies by decreasing the number of smaller vials they currently have to keep in stock. HyperRAB 3-mL (900-IU) was approved by the U.S. Food and Drug Administration (FDA) in November 2019, broadening the company's current HyperRAB portfolio, which presently includes 300 IU/mL potency supplied in 1-mL (300-IU) and 5-mL (1500-IU) vials.

The Report Covers

• Market value data analysis of 2021 and forecast to 2028.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global rabies immunoglobulin market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.